Capoluongo, N.; Mascolo, A.; Bernardi, F.F.; Sarno, M.; Mattera, V.; di Flumeri, G.; Pustorino, B.; Spaterella, M.; Trama, U.; Capuano, A.; Perrella, A. Retrospective Analysis of a Real-Life Use of Tixagevimab–Cilgavimab plus SARS-CoV-2 Antivirals for Treatment of COVID-19. Pharmaceuticals2023, 16, 1493.
Capoluongo, N.; Mascolo, A.; Bernardi, F.F.; Sarno, M.; Mattera, V.; di Flumeri, G.; Pustorino, B.; Spaterella, M.; Trama, U.; Capuano, A.; Perrella, A. Retrospective Analysis of a Real-Life Use of Tixagevimab–Cilgavimab plus SARS-CoV-2 Antivirals for Treatment of COVID-19. Pharmaceuticals 2023, 16, 1493.
Capoluongo, N.; Mascolo, A.; Bernardi, F.F.; Sarno, M.; Mattera, V.; di Flumeri, G.; Pustorino, B.; Spaterella, M.; Trama, U.; Capuano, A.; Perrella, A. Retrospective Analysis of a Real-Life Use of Tixagevimab–Cilgavimab plus SARS-CoV-2 Antivirals for Treatment of COVID-19. Pharmaceuticals2023, 16, 1493.
Capoluongo, N.; Mascolo, A.; Bernardi, F.F.; Sarno, M.; Mattera, V.; di Flumeri, G.; Pustorino, B.; Spaterella, M.; Trama, U.; Capuano, A.; Perrella, A. Retrospective Analysis of a Real-Life Use of Tixagevimab–Cilgavimab plus SARS-CoV-2 Antivirals for Treatment of COVID-19. Pharmaceuticals 2023, 16, 1493.
Abstract
Tixagevimab–cilgavimab are effective for treatment of early COVID-19 among outpatients with risk factors for progression to severe illness, as well as for primary prevention and post-exposure prophylaxis. We aimed to retrospectively evaluate the hospital stay (expressed in days), prognosis, and negativity rate for COVID-19 after treatment with tixagevimab–cilgavimab.
We enrolled 42 patients who were nasal swab positive for SARS-CoV-2 (antigenic and molecular), both vaccinated and not vaccinated for COVID-19, hospitalized at the first division of the Cotugno Hospital in Naples and who received intramuscular single dose of tixagevimab-cilgavimab (300 mg / 300 mg). All patients candidates for tixagevimab-cilgavimab had immunocompromised immune system either for chronic degenerative disorders (Group A: 27 patients) or onco-hematological diseases (Group B: 15patients). Patients enrolled in group A came to our observation after 10 days from the detection of positivity to COVID-19 unlike the other types of patients enrolled in this study. The mean stay in hospital of patients in Group A was 21±5 days vs 25±5 days in Group B. Twenty patients resulted negative after a median of hospitalization stay of 16 days (IQR: 18-15.25), of them 5 (25%) patients belonged to group B. Therefore, patients with active hematological malignancy had the lower negativization rate.
Keywords
COVID19; Tixagevimab–cilgavimab; Remdesivir
Subject
Medicine and Pharmacology, Epidemiology and Infectious Diseases
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
